EpigenoMax Therapeutics is developing an integrated precision oncology platform that combines advanced molecular diagnostics with programmable BioGene therapeutics.

Our approach is designed to help physicians identify the right treatment strategy while delivering highly targeted therapies that address one of the greatest challenges in oncology: treatment resistance.

By integrating diagnosis and treatment into a unified precision medicine strategy, we aim to improve therapeutic effectiveness while creating meaningful value for patients, clinicians and investors.